Important clinical research progress in lung cancer in 2022

Abstract

Lung cancer remains the malignant tumor with the highest morbidity and mortality in China, among which non-small cell lung cancer (NSCLC) accounts for more than 80%. Clinical studies related to adjuvant immunotherapy and neoadjuvant immunotherapy in perioperative NSCLC have been updated. In terms of targeted therapy, the research and development of drugs for rare and difficult-to-treat targets continues to be hot, and the research and development of antibody-drug conjugate gradually becomes hot, which is expected to open a new track for the diagnosis and treatment of lung cancer. Rare target diagnosis and treatment of NSCLC has gradually entered an era of precision and standardization. In terms of immunotherapy for patients with advanced NSCLC, the new regimen of combined immunotherapy is expected to further improve the efficacy. This review, with the focus on advanced NSCLC, summarized the development of NSCLC, discussed current problems and challenges, and proposed prospects on future directions.

Keywords

• |non-small cell lung cancer|perioperative period|targeted therapy|immunotherapy